Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male patients with severe (baseline FVIII less than or equal to 1%) haemophilia A~* Age below 12 years and weight at least 11 kg~Exclusion Criteria:~* Surgery planned to occur during trial participation (exceptions are port placement, dental extractions, and minor, uncomplicated emergent procedures)~* Congenital or acquired coagulation disorders other than haemophilia A~* Any history of FVIII inhibitors (greater than or equal to 0.6 BU/mL)

- Gender: MALE
- Minimum Age: None
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- rFVIII (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).